Erem Cihangir, Civan Nadim, Coskun Hulya, Mentese Ahmet, Suleyman Akile Karacin, Altay Diler Us, Akgul Zeynep, Deger Orhan
Department of Internal Medicine, Division of Endocrinology and Metabolism, Trabzon, Turkey.
Department of Medical Biochemistry, Trabzon, Turkey.
Clin Endocrinol (Oxf). 2016 Jun;84(6):919-24. doi: 10.1111/cen.12955. Epub 2015 Nov 12.
Signal peptide-CUB-EGF domain-containing protein 1 (SCUBE1) has been shown to increase in parallel with platelet activation in acute ischaemic and thrombotic diseases. There has been no study evaluating SCUBE1 levels in patients with overt hyperthyroidism (OHyper) and subclinical hyperthyroidism (SHyper), conditions which are known to show impairment of both endothelial and platelet function. This study sought to evaluate SCUBE1 concentrations in patients with SHyper and OHyper, and assessed the effects of antithyroid drug (ATD) therapy on circulating SCUBE1 levels.
Forty-five untreated patients with OHyper, 20 untreated patients with SHyper and 30 age- and sex-matched healthy controls were prospectively included in the study. Biochemical and hormonal parameters were evaluated in all patients before and after treatment.
Compared with the control subjects, SCUBE1 levels were significantly increased in patients with SHyper and OHyper (P < 0·0001 and P = 0·002, respectively). SCUBE1 levels were not significantly different in patients with OHyper compared with patients with SHyper. There was no significant correlation between serum thyroid hormones and SCUBE1 levels. Plasma SCUBE1 levels decreased significantly in both OHyper and SHyper after ATD treatment (P < 0·05).
Increased SCUBE1 levels in both SHyper and OHyper patients may reflect increased platelet activation and possible endothelial dysfunction, which might augment the risk for atherosclerotic and atherothrombotic complications. SCUBE1 may be used as a reliable marker of endothelial damage in hyperthyroidism, especially in the subclinical period.
含信号肽 - CUB - EGF 结构域蛋白 1（SCUBE1）在急性缺血性和血栓性疾病中已被证明与血小板活化呈平行增加。尚无研究评估显性甲状腺功能亢进（OHyper）和亚临床甲状腺功能亢进（SHyper）患者的 SCUBE1 水平，已知这两种情况均存在内皮和血小板功能受损。本研究旨在评估 SHyper 和 OHyper 患者的 SCUBE1 浓度，并评估抗甲状腺药物（ATD）治疗对循环 SCUBE1 水平的影响。
前瞻性纳入 45 例未经治疗的 OHyper 患者、20 例未经治疗的 SHyper 患者以及 30 例年龄和性别匹配的健康对照者。在所有患者治疗前后评估生化和激素参数。
与对照组相比，SHyper 和 OHyper 患者的 SCUBE1 水平显著升高（分别为 P < 0·0001 和 P = 0·002）。OHyper 患者与 SHyper 患者的 SCUBE1 水平无显著差异。血清甲状腺激素与 SCUBE1 水平之间无显著相关性。ATD 治疗后，OHyper 和 SHyper 患者的血浆 SCUBE1 水平均显著降低（P < 0·05）。
SHyper 和 OHyper 患者中升高的 SCUBE1 水平可能反映血小板活化增加和可能的内皮功能障碍，这可能增加动脉粥样硬化和动脉粥样硬化血栓形成并发症的风险。SCUBE1 可作为甲状腺功能亢进，尤其是亚临床期内皮损伤的可靠标志物。
